1. Home
  2. TME vs VTRS Comparison

TME vs VTRS Comparison

Compare TME & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tencent Music Entertainment Group each representing two

TME

Tencent Music Entertainment Group each representing two

N/A

Current Price

$8.81

Market Cap

16.2B

ML Signal

N/A

Logo Viatris Inc.

VTRS

Viatris Inc.

N/A

Current Price

$16.21

Market Cap

18.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TME
VTRS
Founded
N/A
1961
Country
China
United States
Employees
N/A
30000
Industry
Broadcasting
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.2B
18.7B
IPO Year
2018
2019

Fundamental Metrics

Financial Performance
Metric
TME
VTRS
Price
$8.81
$16.21
Analyst Decision
Buy
Buy
Analyst Count
8
4
Target Price
$19.44
$13.50
AVG Volume (30 Days)
8.0M
10.3M
Earning Date
05-12-2026
05-07-2026
Dividend Yield
2.66%
3.21%
EPS Growth
N/A
N/A
EPS
N/A
0.05
Revenue
N/A
$14,299,900,000.00
Revenue This Year
$10.73
$4.41
Revenue Next Year
$10.19
$1.96
P/E Ratio
$15.69
$320.90
Revenue Growth
N/A
N/A
52 Week Low
$7.94
$9.43
52 Week High
$26.70
$18.39

Technical Indicators

Market Signals
Indicator
TME
VTRS
Relative Strength Index (RSI) 44.12 40.73
Support Level $8.69 $15.82
Resistance Level $9.78 $16.54
Average True Range (ATR) 0.33 0.52
MACD -0.11 -0.20
Stochastic Oscillator 33.24 12.95

Price Performance

Historical Comparison
TME
VTRS

About TME Tencent Music Entertainment Group each representing two

Tencent Music is the largest online music streaming platform in China, established in 2016 through the merger of QQ Music, Kuwo Music, and Kugou Music. Tencent, its largest shareholder, holds over 50% of the shares and more than 90% of the voting rights. Beyond streaming services, Tencent Music generates revenue through a diverse range of offerings, including podcasts, livestreaming, concerts, and karaoke.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: